The effects of heparin on the activated partial thromboplastin time of the College of American Pathologists Survey specimens. Responsiveness, precision, and sample effects.

No abstract is available for this paper.

• Publication year

  1987

• Venue

  Archives of Pathology & Laboratory Medicine

• Publication date

  1987-09-01

• Fields of study

  Medicine

• Identifiers
  PMID 3632297
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Variability in heparin sensitivity of APTT reagents.

  1986cited by this paper
• Heparin monitoring by activated partial thromboplastin time. Comparison of ex vivo measurement and in vitro standardization.

  1985cited by this paper
• Studies of Phospholipid Reagents Used in Coagulation II: Factors Influencing Their Sensitivity to Heparin

  1981cited by this paper
• Heparin kinetics: Variables related to disposition and dosage

  1981cited by this paper
• Laboratory monitoring of heparin. Effect of reagents and instruments on the activated partial thromboplastin time.

  1981cited by this paper
• Relationship between concentration and anticoagulant effect of heparin in plasma of normal subjects: Magnitude and predictability of interindividual differences *

  1980cited by this paper
• Laboratory monitoring of heparin therapy--the effect of different salts of heparin on the activated partial thromboplastin time.

  1980cited by this paper
• Heparin and Partial Thromboplastin Time: an International Survey

  1980cited by this paper
• Heparin and the activated partial thromboplastin time--a difference between the in-vitro and in-vivo effects and implications for the therapeutic range.

  1980cited by this paper
• Heparin: biochemistry, therapy, and laboratory monitoring.

  1979cited by this paper
• The effect of heparin on the activated partial thromboplastin time.

  1978cited by this paper

• [Correlation between aPTT and antifactor Xa to determine therapeutic ranges for unfractionated heparin].

  2014cites this paper
• Evaluation of activated partial thromboplastin time (aPTT) reagents for application in biomedical diagnostic device development

  2011cites this paper
• New oral antithrombotics: a need for laboratory monitoring. Against

  2010cites this paper
• Update on heparin: what do we need to know?

  2010cites this paper
• Quality assurance in hemostasis: the perspective from the College of American Pathologists proficiency testing program.

  2007cites this paper
• Quality Assurance in Hemostasis: The Perspective from the College of American Pathologists Proficiency Testing Program

  2007cites this paper
• Treatment of thromboembolic complications in patients with brain tumors

  2005cites this paper
• Establishing a New Target Range for Unfractionated Heparin for Acute Coronary Syndromes

  2004cites this paper
• Key References: Anticoagulation Monitoring

  2004cites this paper
• Heparin in Vitro Sensitivity of the Activated Partial Thromboplastin Time in Canine Plasma Depends on Reagent

  2003cites this paper
• Vergleichbarkeit der Methoden zur Bestimmung der Aktivierten Partiellen Thromboplastinzeit und der Resistenz gegen aktiviertes Protein C

  2002cites this paper
• A COMPARISON OF THE SENSITIVITY OF APTT REAGENTS TO THE EFFECTS OF ENOXAPARIN, A LOW‐MOLECULAR WEIGHT HEPARIN

  2001cites this paper
• Use of a fixed activated partial thromboplastin time ratio to establish a therapeutic range for unfractionated heparin.

  2001cites this paper
• Anti-thrombotic efficacies of enoxaparin, dalteparin, and unfractionated heparin in venous thrombo-embolism.

  2000cites this paper
• Monitoring Heparin Therapy Using Activated Partial Thromboplastin Time – Results of a Multicenter Trial Establishing the Therapeutic Range for SILIMAT, a Reagent with High Sensitivity to Heparin

  1998cites this paper
• Evaluation of the Activated Partial Thrombo-plastin Time (APTT) Sensitivity to Heparin Using Five Commercial Reagents: Implications for Therapeutic Monitoring

  1998cites this paper
• College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy.

  1998influential citation
• Performance characteristics of a new synthetic APTT reagent.

  1998cites this paper
• Antibodies against the fibrin beta-chain amino-terminus detect active canine venous thrombi.

  1997cites this paper
• Comparison of anti-factor Xa heparin activity and activated partial thromboplastin time in 2,773 plasma samples from unfractionated heparin-treated patients.

  1997cites this paper
• Monitoring heparin treatment with the APTT: the effect of methodological changes on the APTT.

  1996cites this paper
• Wide variability in the sensitivity of APTT reagents for monitoring of heparin dosage.

  1996cites this paper
• Effects of napsagatran (Ro 46-6240), a new synthetic thrombin inhibitor and of heparin in a canine model of coronary artery thrombosis: comparison with an ex vivo annular perfusion chamber model.

  1996cites this paper
• Activated clotting time as an appropriate test to compare heparin and direct thrombin inhibitors such as hirudin or Ro 46-6240 in experimental arterial thrombosis.

  1995cites this paper
• Laboratory diagnosis of hemorrhagic and thrombotic disorders.

  1994cites this paper
• Coagulation screening tests.

  1994cites this paper
• Monitoring Anticoagulant Therapy in the Setting of Thrombolytic Therapy

  1994cites this paper
• [Comparative evaluation of unfractionated and low molecular weight heparins. Results of the French Etalonorme interlaboratory quality control].

  1993cites this paper
• Establishing a Therapeutic Range for Heparin Therapy

  1993cites this paper
• Decentralized testing for prothrombin time and activated partial thromboplastin time using a dry chemistry portable analyzer.

  1993cites this paper
• Clinically significant heparin carryover on the ACL 300R.

  1992cites this paper
• Comparison of heparin and aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction.

  1991cites this paper
• A Comparison of Five Devices for the Bedside Monitoring of Heparin Therapy

  1991cites this paper
• Standardization of the activated partial thromboplastin time for monitoring of heparin therapy: where should we go?

  1989cites this paper
• Standardization of the activated partial thromboplastin time for monitoring of heparin therapy: Where should we go?

  1989cites this paper